Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
NCT02009761
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG:
BI 655064
Sponsor
Boehringer Ingelheim